Redhill Biopharma Ltd., of Tel-Aviv, entered into a definitive agreement with Broadfin Capital LLC for the sale of Redhill’s American Depository Shares and warrants in a private placement for a sum of $2.5 million. Read More
A day after Ophthalix Inc., of Petach Tikvah, Israel, reported that CF101, an A3 adenosine receptor (A3AR) agonist licensed from parent company Can-Fite Biopharma Ltd., failed to meet primary and secondary efficacy endpoints in a Phase III study in moderate-to-severe dry eye syndrome, Ophthalix is planning a retrospective analysis of its Phase III dry eye syndrome study data to determine if there is a correlation between the A3AR biomarker and patients’ response to CF101. Read More
As 2013 ticked away, Intrexon Corp. extended a string of biotech deals by inking an exclusive channel collaboration (ECC) with Agilis Biotherapeutics LLC, which simultaneously launched with an $8 million financing. Read More
Over the past few years, clinicians have achieved near-miraculous feats in terms of survival of extremely preterm infants. Delivery even at 25 weeks – not too much after the halfway mark of a full-term pregnancy, and a time point at which premature babies were once born only to die – now has a survival rate of 50 percent. Read More
LONDON – With Humira leading the way as the world’s best-selling drug, biologics now account for an increasing proportion of the pharma industry’s turnover and of its pipeline. Read More
In one of its last precedential opinions of 2013, the U.S. Court of Appeals for the Federal Circuit overturned a Patent and Trademark Office (PTO) decision Monday and gave it a reading lesson in obviousness and prior art. Read More
Cardium Therapeutics Inc.’s first data from the first stage of its Phase III trial with its gene therapy Generx (alferminogene tadenovec, Ad5FGF-4) in patients with myocardial ischemia due to arteriosclerosis were favorable enough that the firm is accelerating the study, with interim data in the first half of next year. Read More
Two biotech companies, Argos Therapeutics Inc. and Eleven Biotherapeutics Inc., slid initial public offering (IPO) filings under the wire for 2013 to raise $60 million and $69 million, respectively. The filings cap a spectacular year for IPOs. Thirty-seven biotechs successfully completed IPOs in 2013, raising about $3 billion. Argos and Eleven will join 15 other companies filed and pending for 2014. Read More
